{"entity":{"id":"nct06096779","kind":"trial","name":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr","aka":[],"tldr":"A phase 2 trial of Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Genentech, Inc., active and no longer recruiting.","summary":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis is a phase 2 interventional study registered as NCT06096779 by Genentech, Inc., with 30 participants enrolled, started 2024-07-15 and due to reach its primary completion in 2027-07-30. Interventions recorded: Atezolizumab, Bevacizumab. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06096779","url":"https://clinicaltrials.gov/study/NCT06096779"}],"tags":["ctgov-ingest"],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":["atezolizumab","bevacizumab"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06096779","phase":"2","setting":"A Phase II, Open-label, Multi-cohort, Multicenter Study in Patients With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis","sponsor":"Genentech, Inc.","enrolled":30,"outcomes":[]},"route":"/trials/nct06096779/","neighbours":{"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}]}}